Relay Therapeutics' zovegalisib shows 60% response in mid‑stage trial for rare vascular anomalies

Relay Therapeutics reported early data from a phase 2 trial of its experimental drug zovegalisib in patients with vascular anomalies, a group of rare disorders characterized by abnormal blood vessel growth.

In the study of 20 participants treated for 12 weeks, the drug achieved a 60% overall response rate, with most patients showing symptom improvement across various disease subtypes and those carrying PIK3CA mutations.

While dosing had to be reduced for about a quarter of the cohort receiving the highest dose, no participants stopped treatment; adverse events were described as low‑grade, manageable and reversible, suggesting the therapy could be suitable for chronic use.

The positive readout lifted Relay’s share price roughly 10% in early trading, and the company plans to advance the candidate into further testing, positioning it as a potential competitor to Novartis’ Vijoice.